Next Article in Journal
Anti-Atherosclerotic Effects of Fruits of Vitex rotundifolia and Their Isolated Compounds via Inhibition of Human LDL and HDL Oxidation
Previous Article in Journal
CRISPR/Cas9-Mediated Multiplex Genome Editing of JAGGED Gene in Brassica napus L.
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomolecules
Volume 9
Issue 11
10.3390/biom9110726
biomolecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Viral Infections and Interferons in the Development of Obesity

by
Yun Tian
†,
Jordan Jennings
†,
Yuanying Gong
† and
Yongming Sang
*
Department of Agricultural and Environmental Sciences, College of Agriculture, Tennessee State University, 3500 John A. Merritt Boulevard, Nashville, TN 37209, USA
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Biomolecules 2019, 9(11), 726; https://doi.org/10.3390/biom9110726
Submission received: 14 October 2019 / Revised: 8 November 2019 / Accepted: 9 November 2019 / Published: 12 November 2019
(This article belongs to the Section Biological Factors)
Browse Figures
Review Reports Versions Notes

Abstract

:
Obesity is now a prevalent disease worldwide and has a multi-factorial etiology. Several viruses or virus-like agents including members of adenoviridae, herpesviridae, slow virus (prion), and hepatitides, have been associated with obesity; meanwhile obese patients are shown to be more susceptible to viral infections such as during influenza and dengue epidemics. We examined the co-factorial role of viral infections, particularly of the persistent cases, in synergy with high-fat diet in induction of obesity. Antiviral interferons (IFNs), as key immune regulators against viral infections and in autoimmunity, emerge to be a pivotal player in the regulation of adipogenesis. In this review, we examine the recent evidence indicating that gut microbiota uphold intrinsic IFN signaling, which is extensively involved in the regulation of lipid metabolism. However, the prolonged IFN responses during persistent viral infections and obesogenesis comprise reciprocal causality between virus susceptibility and obesity. Furthermore, some IFN subtypes have shown therapeutic potency in their anti-inflammation and anti-obesity activity.

1. Viral Infectobesity: The Association of Chronic Viral Infections with Obesity

According to recent statistics, the prevalence of obesity was 39.8% and affected about 93.3 million US adults in 2015~2016 [1]. Similarly, in many other countries worldwide, overweight and obesity are also dramatically on the rise, particularly in urban areas [2]. We face an obesity epidemic that has a complex and multifactorial etiology [3]. While obesity is multifactorial, a simplified thermo-dynamic model, rather than a biological model, has prevailed in obesity clinics for over 90 years [3]. A key suggestion of this simplified model is to cut down one’s calorie intake and exercise more. While addressing proximate causes of obesity serves as a global health priority, it seems incomplete or ineffective to control obesity given that the epidemic has continued to worsen at the global level [1,2,3]. Recent investigations postulate that both physics and biology have tremendous utility for understanding obesity. In this regard, we review the biological complex of obesity and interpret its etiology from the interaction between immune and metabolic systems (i.e., immunometabolism). As pointed out by Hotamisligil [4], metabolic and immune systems are among the most fundamental requirements and are highly inter-dependent for species survival. Sequentially, obesity displays itself as a metabolic overload (shown by excess adipose tissue) in addition to an immune disorder, which accompanies a low-grade inflammatory state known as “meta-inflammation” involving both reprogrammed immune cells and adipocytes [4]. Immunologically, chronic inflammation accompanies persistent infections (either locally or systemically) as well as microbiota dysbiosis [5,6,7,8,9,10,11,12]. In addition, persistent infections could also retain energy storage via adipogenesis at adipose depots for immune preparation [5,13,14]. The visceral adipose depots in mammals, as counterparts of the insect fat body which functions as both a storage and an immune organ, may evolutionarily enhance their role in anabolic storage for combat readiness when facing long-term defense risks posed by pathogenic persistence [4,11,12,13,14]. In this context, recent studies have associated obesity with numerous microbial agents in both humans and animal models—a phenomenon described as infectobesity [15,16,17]. Microbial infections generally beget inflammation and alter metabolic function in surrounding cells or even systemically in the animal body. In this review, we recap the evidence of viral agents in association with obesity and relevant metabolic syndrome [13,14,15,16,17]. In addition to examination of the major viruses or virus-like agents (VLA) that have been associated with obesity, we emphasize shared immune responses underlying the viral infectobesity. With this regard, interferons (IFNs), as a group of crucial cytokines in regulation of antiviral and autoimmune processes, are key to understanding the pathogenesis of persistent viral infections that are associated with most, if not all, viral infectobesity [11,12,18,19]. In addition, the effect of IFNs and IFN-mediated signaling pathway (collectively known as the IFN system) in reprograming cellular lipid metabolism provides a biochemical mechanism to understand the interaction of viral infection and obesity [4,5,11,19].
As shown in Table 1, the major viruses and VLA that have been associated with obesity in both humans and animal models include members of adenoviridae, herpesviridae, phages, transmissible spongiform encephalopathies (slow virus), and hepatitides [15,16,17]. The additions to this list also include Dengue fever virus (DENV) and HIV (which belong to Flavivirade and retroviridae, respectively) in patients post the viral infections entering into a latent phase [20,21,22,23,24]. Voss and Dhurandhar (2017) rationalized the biological plausibility of infectobesity caused by these viruses [15], which included: (1) direct roles of some viruses to reprogram host metabolism toward a more lipogenic and adipogenic status; (2) the probability that humans may exchange microbiota components (emphasizing its viral component, i.e., virome/virobiota) from livestock reservoirs that have been aggressively selected for efficient weight/fat gain; and (3) the adaptation of host immune and metabolic system under persistent viral infections [15,16,17,18]. With regard to these, we emphasize the sequential immuno-metabolic adaption to persistent viral infections, especially the subverted IFN response, which emerges as a key drive for adipogenesis and obesity-associated immune suppression. This, in turn, underlies reciprocal causality between obesity and higher susceptibility of obese individuals to viral infections [11,12,13,14,15,16].
To recap the evidence of viral infectobesity, adenoviruses (Ad) including an avian isolate from India (SMAM-1) and several serotypes of human Ad have been associated with obesity regarding epidemiological correlation in certain subsets of humans and animals [15,24]. In addition, as SMAM-1 infection caused fat gain and high body mass index (BMI) in both birds and probably humans. At least five human Ad serotypes including Ad-5, -9, 31, -36, and -37 have been observed to cause obesity at different levels. First, these five Ad serotypes induced adipocyte differentiation and increased lipid synthesis in cultured animal fibroblasts or pre-adipocytes. Second, Ad-5, Ad-37, and particularly Ad-36 infections increased the adipose index in animal models including chickens (Ad-36 and -37), mice (Ad-5 and -36), rats, and marmosets (Ad-36). Third, Ad-5 has been associated with child obesity and Ad-36 in both adults and children [15,24]. Mechanistically, Ad-36 infection activates peroxisome proliferator activated receptor-γ (PPARγ) (which is the so-called master-switch of adipocyte development) to signal adult stem cells to become adipocytes; meanwhile, the virus also induces the expression of some cell glucose transporters to facilitate energy supply [25,26]. In addition, adenoviral E4orf1 protein (early region 4 open reading frame 1) was identified as a viral mechanism mediating acute adipogenesis in cells and animals [27,28]. Similarly, all other viruses and VLA listed in Table 1 have also been associated with obesity in animals and humans through pathological studies or epidemiological observations; however, other viral mechanisms (such as viral factors regulating inflammatory response and lipogenesis in adipose depots) directly engaged in adipogenic effects warrant further investigation [15,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45]. Notably, because phages do not directly infect animal cells, these bacterial viruses plausibly exert an adipogenic effect by affecting the symbiosis of microbiota [31,32,33,34]. The adipogenic observation in the patients of prion diseases (or coined as “slow viruses” previously), is plausibly ascribed to host immuno-metabolic adaptation to the chronic pathogenesis during disease progress, because no adipogenic effect has been associated to the prion protein [15,37,38,39,40,41,42]. In this context, we emphasize that host immuno-metabolic adaptation to prolonged viral infection comprises a common etiology for viral infectobesity. As multiple immune factors, particularly inflammatory cytokines (such as IL-1, IL-6, and TNF-α) and adipokines (such as leptin and adiponectin), have been well-addressed elsewhere in obesity, we highlight the regulatory role of the IFN system in immunometabolic regulation in the scenario of viral infectobesity [4,11,12,30].

2. IFNs Emerging as a Key Factor to Mediate Viral Persistence and Relevant Infectobesity

Interferons (IFN) are vital antiviral cytokines evolved in vertebrates. Host cells secrete three types of IFN peptides (i.e., type I, II and III IFNs) in response to viral infections. Three types of IFNs not only differ in their molecular signatures and bind to distinct cell receptors, but also play distinct tissue/cell-specific roles in control of viral infections. In brief, the innate immune IFNs, which include multiple subtypes of type I and type III IFNs, provide early and local protection during viral entry into animal portals. In contrast, IFN-γ, as the only member of type II IFN, is primarily produced by specific immune cells (including natural killer cells (NK) and activated T cells) to mediate adaptive immunity for eliminating dangerous pathogens that evade innate immunity [11,12,46,47,48,49]. Persistent viral infections result from the virus escaping from immune clearance and entering into a co-existing stage within the host cells to avoid excessive damage. The mechanisms to maintain persistent viral infections are incompletely understood, but believably involve both modulation of viral actions and reprograming of the host metabolic and immune responses [11,12,49]. Previous studies in mouse models proposed that ineffective adaptive immune responses including lack of effective cytotoxic T cells (CTL) and neutralizing antibodies are needed for viral persistence [11,12]. However, recent studies indicate that innate immune IFNs are necessary in the regulation of viral infections during both early and persistent phases [11,12,46,47,48,49]. Such as in mice infected by norovirus (MNV) and lymphocytic choriomeningitis virus (LCMV), IFN-α/β played a systemic role in control of the viral replication and clearance; and IFN-λs were effective in clearing enteric persistence of MNV [12,49,50]. Therefore, innate immune IFNs preside over antiviral immunity to intervene chronic viral infection through mediating at both innate (stimulation of expression of a plethora of ISG expression) and adaptive immune levels (exerting either positive or negative impacts on CTL and B-cell functions) [49,50,51]. Numerous studies in HCV, HIV-1, and simian immunodeficiency virus (SIV) as well as multiple viruses in livestock species place sustained type I IFN expression as a common nexus in the pathogenesis of multiple chronic diseases [11,12,49]. Regarding viral pathogenesis, IFN responses during the acute phase of viral infections is immuno-stimulatory and antiviral effective; however, the prolonged IFN production (particularly of type I IFNs) in response to viral persistence is emerging as a double-edge sword actually driving inflammation and immunosuppression [12,49,50,51]. In this context, examination of reported studies about viral infectobesity indicates that most, if not all, of these obese situations correlate to the chronic phases or persistent stages of viral infections (Table 1) [11,12,13,14,15,16,17]. In addition, the antagonism to the host IFN system comprises a major mechanism of viruses that are capable of being persistent or even harnessed as components of the host microbiota (virobiota) [52,53,54,55,56,57,58,59,60,61,62]. In other words, the prolonged IFN response observed during most chronic viral pathogeneses may underlie, at least partly, the immune dysfunction [11,12] that triggers metabolic disorders and obesity (Table 1) [4,13,14,15,16,17,63].

3. Gut Microbiota and Intrinsic Interferon Response

Current studies link gut microbiota to the development of obesity and its related comorbidities in the following aspects [64,65,66,67]. First, changes of gut microflora affect adipogenesis or the pathogenesis of obesity. It has been shown that healthy individuals have highly diverse gut microbiota than those with obesity. The association of some bacterial taxonomic groups with obesity and relevant comorbidities was observed such as lower content of Bacteroidetes in obese people and the association of Lactobacillus and Clostridium with insulin resistance. These findings indicate that the disorder of gut microflora could be a drive to obesity development. Second, germ-free (GF) animal models provide eloquent evidence to address the role of gut microbiota in obesity induction. Without gut microbiota colonization, GF mice were highly resistant to obesity induced by a high-fat diet than normal mice despite high food intakes. Furthermore, GF mice that received fecal microbiota transplantation (FMT) from an obese donor had higher weight gain than those receiving it from a lean donor. Misuses and overuses of antibiotics in the animal industry and human medicine impact on gut microbial ecology, leading to antibiotic resistance. Relevant studies using sub-therapeutic antibiotic treatment indicated that it selectively eliminated vulnerable taxonomic groups of the gut microbiome, thus altering microbiome composition that results in elevated hepatic metabolism of lipids and cholesterol in young mice [64,65,66,67]. Mechanistically, gut microbiota affect obesity development in an inter-systemic manner. Locally in the gut, obesity-associated gut microbiota were selected for three properties: (1) a more efficient harvest of energy from the diet; (2) gene reprogramming to facilitate energy anabolism; and (3) secretion of bioactive molecules and hormones to affect host appetite. The decrease in gut microbiota diversity in obese individuals impaired the intestinal barrier function and disturbed immune homeostasis by inducing low-grade inflammation, which was considered an early trigger for adipogenesis [64,65]. Along with microbiome decomposition, the microbial shedding molecules such as liposaccharides (LPS) induce further gut inflammation and immune-cell infiltration. Short-chain fatty acid (SCFAs) released by microbiota directly fuel insulin-mediated lipogenesis and promote adipocyte differentiation. Beyond the gut, the dysbiosis of gut microbiota also signals inflammation and hepatic T cell infiltration to manifest as fatty liver frequently associated with obesity. Gut microbiota can also directly signal gut afferent neurons and mediate the secretion of appetite hormones to regulate host metabolism through the gut–brain axis and an endocrine pathway [66,67]. Therefore, collected evidence indicates that local alteration in gut microbiota will lead to systemic reprograming in energy and lipid metabolism, immune response, and endocrine functions that culminate in obesogenesis [64,65,66,67].
However, a majority of current studies about microbiota focus on cellular microbiome (including bacteria, archaea, fungi, and protozoa), but overlook the viral community (i.e., virobiota or virome) where it is at least ten-fold over more numerous than its cellular counterpart [68,69,70,71]. Indeed, a human individual regardless of health status contains at least a dozen taxa of eukaryotic viruses and bacterial phages. While phages potentially affect obesity indirectly through modulating bacterial composition, eukaryotic viruses can directly interact with host cells to result in an ideal commensalism (symbiosis) or cause either symptomatic or asymptomatic pathogenesis (dysbiosis). Compared with wild-type mice, significantly higher viral contents were detected in the feces of obese mice. It was also indicated that increased viral content, particularly viral RNA, was tightly correlated with an increase of fat mass and potential hyperglycemia. Only total viral DNA/RNA mass was compared in this study, but the viral taxonomic classification was not performed using metagenomic approaches [70]. However, their data indicated that this obesity-correlated increase of viral content was mostly ascribed to phages [70]. This reinforces the points from several recent reviews that the gut virome is a missing link underlying human diseases like cancers and obesity [68,69,71]. Further studies are needed to decipher the composition of gut commensal viruses and their role in obesogenesis through direct interaction on host cells [67,68,69]. Despite the lack of studies to correlate certain viral taxonomic groups with obesity in humans and animals, they may have an overlapping spectrum with most persistent viruses associated with obesity (Table 1) [13,14,15,16,17,68,69,70,71].
Evolutionarily, the IFN system represents a signature antiviral mechanism in high vertebrates. The molecular evolution diversifies three types (type I, II, and III) and multiple subtypes/isoforms within type I and type III IFNs. IFN-γ, as the single type II IFN, is mainly produced by NK cells and CTLs and mediates pro-inflammatory response along with the activation of adaptive immune cells. Type I IFNs such as IFN-α/β are expressed by most nucleated cells; in contrast, type III IFNs are produced and active primarily in epithelial cells [11,18,46,51]. Even though type I and III IFNs activate similar downstream signaling cascades in their responsive cells, respectively; type III IFNs (IFNλs), unlike type I IFNs, do not elicit strong inflammatory responses in vivo [72]. The effects in inflammatory induction of type I IFNs are more complicated. It depends on their subtypes, tissue location, and even temporal phases during viral pathogenesis. For example, the universal IFN-α/β subtypes may induce more pro-inflammatory response than IFN-κ or IFN-ε, which have a restrictive expression in keratinocytes or the reproductive tract, respectively [51,71]. In addition, the sustained IFN-α produced during persistent viral infections elicits more inflammatory cytokine responses [11,12]. Nevertheless, most of these antiviral IFN responses were observed during the infection of pathogenic viruses. However, several recent studies discovered that, in addition to the robust IFN reaction to infectious viruses, there is always an intrinsic IFN production signaled by gut microbiota [73,74,75]. In homeostatic situations, gut epithelia and the underlying leukocytes (including NK cells, macrophages, and dendritic cells) sense the natural shedding of microbial molecules from microbiota and sustain an intrinsic expression of innate immune IFNs, particularly IFN-β and probably also the epithelial IFN-λ subtype [72,73,74,75]. Acting through a non-canonical AKT-mTOR pathway (IFN-β) or an IRF1-indolent process (IFN-λ), these intrinsic or local IFNs signal the expression of some anti-inflammatory and cell growth cytokines including IL-10 and IL-13 to maintain an anti-inflammatory microenvironment, which buffers a homeostatic resistance to meta-inflammation in obesity (Figure 1) [76,77,78]. Using hydrodynamic gene transfer to increase peripheral IFN-β1 in mice fed a high-fat diet, a recent animal trial showed that overexpression of Ifnb1 gene sequentially blocked adipose tissue expansion and body weight gain, independent of food intake [79]. Although more investigations are needed, it is logical to think that the gut virome, especially the “commensal” part should contribute to signaling the intrinsic IFN-β response by microbiota. This thought is largely backed by the role of the gut virome in modulating microbiome composition (such as by phages) as well as more sensitive IFN-inductive effects from viral PAMPs compared to bacterial components [51,77].

4. Regulation of Energy and Lipid Metabolism by Interferons

Instead of directly suppressing or killing viruses, IFNs restrict viruses through induction of hundreds IFN-stimulated effector genes (ISGs) and alter cells to limit virus replication and spreading. These cellular alterations include changes in protein synthesis, energy rebalance, lipid metabolism, membrane composition, and cell proliferation [51,77]. We focused on their role in lipid metabolism to highlight this functional aspect of IFNs because it is plausibly associated with adipogenesis and has been overlooked by most studies of IFN biology in antiviral response [18,80,81,82].
Cell membranes provide a pivotal role and serve as a platform in viral life cycles from entry and replication to assembly and exit. Indeed, the biochemical properties of cell membranes such as fluidity, raft-domain structure, and lipid composition are among the major determinants affecting different stages of viral infections [80,81,82,83,84]. In this context, both cholesterols and sphingolipids (including ceramide) not only affect viral entry, replication, and exit for being structural components that determine the biochemical property of cell membranes, but also actively serve as lipid signaling and direct antiviral molecules to regulate both cellular antiviral responses as well as viral life cycles [83,84]. For example, cholesterol is fundamental for most flavivirus infections in both mammal and insect cell models [85], and 25-hydroxycholesterol (25HC) acts broadly to inhibit viral entry and replication [86]. Similarly, ceramide is an effective sphingosine-derived lipid that regulates diverse cellular immune responses and was recently shown to directly inactivate influenza virus replication [87]. On the other hand, viral infections also extensively modulate (and even actively hijack) cellular lipid metabolism to benefit viral entry and replications. The readers may refer to several recent reviews for details on this topic [83,84,85].
In Figure 2, we illustrate the major effect of type I IFNs in the regulation of cellular energy and lipid metabolism from recent and early studies [88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105]. For energy metabolism, type I IFNs enhance glucose uptake in both mouse embryonic fibroblasts and human plasmacytoid dendritic cells (pDCs) [18,88,89,90,91]. Similarly, IFN-induced increases of glycolysis, oxidative phosphorylation, and ATP production derived from the TCA cycle have been observed in multiple human cells including macrophages, DCs, T cells, keratinocytes, and some cancer cell lines [18,80,81,91,92,93,94]. Particularly in macrophages, IFNs also act on the cellular TCA cycle to stimulate the synthesis of reactive oxygen species (ROS) and itaconic acid to augment the cell antimicrobial activity against engulfed pathogens [82,89,95,96,97,98]. The IFN suppression of lipid metabolism is multifaceted, and can occur by directly repressing the synthesis of fatty acid (FA) and cholesterol in HeLa cells, and by regulating the upstream mediators of AMPK and mTOR complex in several human and mouse cells [99,100,101,102,103,104]. Similarly, in livestock cells, we determined that IFNs exert potent antiviral and immunomodulatory activities through interaction with the metabolic system [76]. The expression of IFNs is regulated either by the nutrient sensor mTOR, or by direct reprograming of the lipid metabolic pathways. Thus, a mutual relationship between IFN production and metabolic core processes is manifested in antiviral responses [4,76,99,100,101,102,103]. For example, type I IFNs induce the synthesis of 25-hydroxycholesterol (25HC), a potent metabolite in cholesterol metabolism that exerts a broad antiviral activity and suppressive effect in production of inflammatory cytokines including IL-1 and TNF-α [82,86,96]. In addition, type I IFNs also promote the cross-membrane import of cholesterol and FA into the cells and strengthen membrane rigidity in multiple human cells [80,81]. Potentially, lipogenesis is a sub-effect of the IFN antiviral activity via increase of 25HC synthesis and cholesterol/FA import, particularly under a situation of persistent viral infections. Plasma ceramide and dihydroceramide levels are a biomarker of insulin resistance and obesity, and molecular manipulation of body ceramide to control obesity was illuminated by a recent elegant study [104]. Notably, other reports indicated that both IFN-γ and IFN-β are potent to regulate ceramide metabolism [104,105]. Taken together, the effective IFN response during acute phases of antiviral responses may actually suppress meta-inflammation and reduce energy flow toward lipogenesis in adipocytes. However, the prolonged IFN responses during chronic viral infections might be an adipogenic drive and could lead to immune suppression mostly in obesity patients (see Figure 3 and the next section) [80,81].

5. Interferon Responses Underlying the Reciprocal Causality of Obesity and Persistent Viral Infections

The association of obesity with various viral infections has always faced a “chicken or egg” disputation [13,14,15,16,17]. Do viral infections trigger the infectobesity first, or does obesity lead to higher susceptibility to viral infections that manifest the comorbidity? As described above, we reinforced the reciprocal causality of viral infections and obesity underlying the infectobesity [14]. First, multiple viruses and VLAs have been epidemiologically associated with obesity and some with identified mechanisms in adipogenic or lipogenic induction (Table 1) [13,14,15,16,17]. As more infectious agents beyond viruses are associated with obesity, we propose an immuno-pathological explanation about pathogenic persistence and subverted immune deviation (such as prolonged IFN-α response irritated during chronic viral infections) is a theme underlying viral infectobesity [11,12,16,19]. As depicted in Figure 1, the intrinsic gut IFN-β response and early mucosal IFN-λ response to acute viral infections generally promote less inflammation and cause negligible tissue damage [72,73,74,75]. However, the later and particularly prolonged type I IFN response during the viral persistence entails a systemic inflammatory response in terms of the induction of pro-inflammatory cytokines (including IL-1, IL-6, and IL-18 in myeloid cells and TNF-α from monocytic cells) and activation of inflammatory lineages of macrophages, NK cells, and hepatic T cells [11,12,106,107]. Systemic and adipose tissue-specific meta-inflammation, manifested by these inflammatory cytokines and immune cells, are exaggerated by the immune responses induced by both viral persistence and some obesogens, which sustain obesogenesis and complicate into infectobesity [4,7,64,66].
On the other hand, obesity also provokes an aberration in the immune system including the attenuated and prolonged type I IFN response that shows antiviral inefficacy. Obese individuals have a high level of blood leptin, implying a situation of “leptin resistance”. Leptin potentially upregulates the suppressor of cytokine signaling-3 (SOCS-3). SOCS3 upregulation and altered systemic leptin levels could be responsible for the reduced type I IFN response as well as other immune dysfunction relevant to T cells and B cells in people with obesity [4,14,19,77,106]. IFN signaling occurs via the same JAK–STAT pathway and is negatively regulated by SOCS-3, suggesting a potential mechanism by which IFN responses to viral infections may be suppressed in obese individuals [14,48]. Teran-Cabanillas et al. (2017) have recently evaluated the effect of SOCS expression and type I IFN responses in obese patients, showing that basal SOCS-3 expression was increased in obesity and correlated to the reduction of type I IFN and pro-inflammatory cytokine responses [48]. This obesity-associated immune dysfunction, particularly attenuated IFN responses, resulted in potential increase of host susceptibility to viral infections; therefore leading to increased prognoses of associated viruses from secondary infections, co-infections, and even opportunistic infections in obese patients. A collection of data from clinical cases in humans and studies in mouse models showed that obese individuals exhibited higher susceptibility and mortality during seasonal and epidemic flu infections [5,108]. More severe lung inflammation and lung damage from viral pneumonia as well as prolonged viral shedding were observed in both obese mice and human cases. It was schematically summarized that multiple immune responses including IFN-α/β production and IFN-signaling of ISG production were impaired in the respiratory epithelial cells and macrophages of obese individuals, along with the increase of inflammatory cytokines and M1 polarization of lung macrophages [5,108]. Therefore, the deficiency of IFN production and signaling in obese patients might be among the risk factors for severe outcomes in pandemic influenza infection [5,14,108]. In one report, the incidence of DENV infections seemed higher in obese patients, but needed more epidemiological evidence to justify [20,21]. In the cases of HIV and HCV infections, the persistence of viral infections in obese patients was complicated by accompanied ART or IFN therapies, respectively [22,23,43,44,45,60]; however, evidence from another side suggests that persistent viral infection and perturbation of IFN signaling exacerbate obesity development. Regarding systemic interaction in animal and human bodies, high-fat diet and viral infection (particularly chronic viral infections) may synergistically (or independently sometime) induce dysbiosis of gut microbiota and systemic low-grade inflammation. These systemic changes partially result from attenuated and prolonged IFN production upon persistent viral infections and underlie the systemic inflammation observed in obesity [4,11,12,13,14,15,16,17]. A recent study by Ghazarian et al. (2017) showed that type I IFN–driven activation of CD8+ T cells in the liver correlates with insulin resistance in obesity-linked fat liver (termed nonalcoholic fatty liver disease, NAFLD) in obese patients [107]. This study also critically associated gut microbiome with liver IFN signaling and its role in driving inflammation in the livers of obese mice [107]. It is likely that the dysbiotic microbiome in the obesity and NAFLD patients may harbor persistent infections. In turn, through over-production of long-chain fatty acid (LFA) and leptin by expanding adipocytes, obesity is accompanied with general immune suppression including aberration of antiviral IFN signaling, which leads to high susceptibility to viral infections (Figure 3) [4,11,48,107,109]. Therefore, in most cases of infectobesity, obesity and viral infections may interact dynamically as a reciprocal causality rather than a simple sequential relationship of “chicken or the egg” [14]. Moreover, IFN (particularly type I IFNs) responses have recently been postulated as a central immunological axis that governs adipocyte differentiation and T cell pathogenicity during obesity-associated metabolic disease [107,108,109]. All these observations collectively indicate that IFNs may directly reprogram cellular lipid synthesis and transport, in addition to its indirect effect through interaction with viral infections.

6. Prospects of Interferon-Based Anti-Obesity Therapies

The emerging theme of IFNs as a critical regulator of obesity has been demonstrated by several reports targeting therapeutic development against obesity in both cell and animal models. McGillicuddy et al. (2009) reported that IFN-γ treatment reduced insulin-stimulated glucose uptake in human adipocytes, attenuated insulin sensitivity, and suppressed differentiation of pre-adipocytes to the mature phenotype. The anti-adipogenic effect of IFN-γ is most likely mediated via sustained JAK-STAT1 pathway activation [110]. Using a mouse model, another study detected the stimulation of type I IFN responses by long chain FA in murine hepatocytes and macrophages. Targeting abrogation of IFN-signaling in adipose tissue, but not hepatocyte-specific deletion of Ifnar1 worsened HFD-induced metabolic syndrome. Conversely, improved metabolic control in laparoscopic adjustable gastric banding patients with obesity was associated with stimulation of type I IFN-regulated genes in subcutaneous adipose tissue and liver [111]. This study indicated the differential role of IFN-signaling through the regulation of different sets of ISGs (such as IRFs, IFITs, MX1, and OAS1) in different cells (particularly adipocytes/hepatocytes) that are closely relevant to the development of obesity and metabolic disorders [111]. Again, using hydrodynamic gene transfer to elevate and sustain blood concentration of IFN-β1 in mice suppressed immune cell infiltration and production of pro-inflammatory cytokines, and blocked adipose tissue expansion and body weight gain, independent of food intake [79]. However, such expression may boost a super-physiological and potentially persistent level of IFN-β in the liver. Yet, persistent IFN-β signaling could induce partially immune exhaustion both centrally and locally and would require further study for pharmaceutic safety. Metabolically, IFN-β1, as an intrinsic responder to gut interaction with its microflora (including virome), has been experimentally shown to improve insulin sensitivity and glucose homeostasis in obese mice [46,79]. These findings, even though preliminary, suggest that targeting IFN signaling represents a promising strategy to block obesity development and its related pathologies. So, how about other IFN subtypes besides type II IFN-γ and type I IFN-β? Ying et al. (2014) administered IFN-τ, a ruminant IFN subtype acting as a signaling molecule during pregnancy in trophoblasts, into obese mice induced by HFD [112]. They showed that this livestock IFN subtype not only significantly mitigated obesity-associated systemic insulin resistance and adipose inflammation by controlling macrophage polarization, but also had less cytotoxic effect than typical IFN-β subtype, indicating a therapeutic potential through cross-species screening of IFN molecules [46,79,111,112]. We know that type I IFNs are eminent for their unconventional subtypes, which are functionally prone to anti-inflammatory and reproductive regulation in livestock species such as pigs and cattle as well as type III IFNs that are restricted to epithelial expression [46]. Information from the study of tissue-specific IFN-signaling effect by Wiser et al. (2018) implies that epithelial IFN-signaling has limited regulation on metabolic and hepatic diseases [111]. Based on these insightful studies for IFN-based anti-obesity therapies, a cross-species and family-wide screening of the most effective IFN ligands is needed, and may provide more IFN-based options for therapeutic optimization against current obesity prevalence and reveal IFN subtypes that bear superior activity in anti-obesity or metabolic regulation to IFN-β or IFN-γ [46,79,110,111,112].

7. Conclusive Remarks

Interferons, as a family of key cytokines, exert broad antiviral, anti-tumor, and anti-proliferative activities in vitro and in vivo [11,18,46,51]. The broad activity of IFNs depends on inducing hundreds of ISGs, which not only directly restrict virus infections at different stages of viral life cycle, but also orchestrate cell metabolism to enter into an antiviral state [11,51]. In this manner, IFNs have been found to play a role in reprogramming cell lipid metabolism in addition to their activity in coordinating RNA and protein metabolism [80,81,88]. This underpins a metabolic basis of IFNs in the development of obesity, and particularly, the infectobesity involving viral infections [13,14,15,16,17]. Effective IFN responses, especially those mediated by type I and type III IFNs, are postulated to be an immunological axis that determines antiviral defense. However, the futile and prolonged IFN response accompanying persistent viral infections actually compromise body function in both antiviral immunity and metabolic normality [11,12]. On the other hand, the cross-talking of leptin and LFA with IFN signaling provides another rationale to associate IFNs with obesity [29,48]. However, more direct evidence such as using IFN-signaling deficient animal models are needed to conclusively determine if and how fundamental IFN signaling plays a role in obesity development. Remarkably, all immune responses are a double-edged sword, as it is for IFN-signaling [11,12,19,50,51]. Although the intrinsic and properly stimulated IFN responses are favorable for antiviral and anti-obesity effect; on the other hand, there are multiple literatures also suggesting that improper IFN responses may actually impair viral clearance, and promote hepatic and metabolic diseases [19,50,51,107]. Thus, for the development of IFN-based therapeutics for anti-obesity purposes, effective IFN regimens need to be selected and tested dynamically to overcome potential side-effects such as those manifested from antiviral IFN therapeutics [113].

Funding

This work was primarily supported by NIH P20-RR017686 (KSU), and in part by USDA NIFA 2018-67016-28313, USDA NIFA Evans-Allen-1013186, and NSF-IOS-1831988 to Y.S. through a resource sharing plan.

Acknowledgments

We thank Frank Blecha and his laboratory at Kansas State University for collaborating in animal/material resources and idea discussion during the completion of relevant research projects that have generated results reviewed here.

Conflicts of Interest

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

  1. Adult Obesity Facts. Available online: https://www.cdc.gov/obesity/data/adult.html (accessed on 15 July 2019).
  2. Obesity. Available online: https://www.who.int/topics/obesity/en/ (accessed on 15 July 2019).
  3. Ludwig, D.S.; Friedman, M.I. Increasing adiposity: Consequence or cause of overeating? JAMA 2014, 311, 2167–2168. [Google Scholar] [CrossRef] [PubMed]
  4. Hotamisligil, G.S. Inflammation, metaflammation and immunometabolic disorders. Nature 2017, 542, 177–185. [Google Scholar] [CrossRef] [PubMed]
  5. Honce, R.; Schultz-Cherry, S. Impact of obesity on influenza A virus pathogenesis, immune response, and evolution. Front Immunol. 2019, 10, 1071. [Google Scholar] [CrossRef] [PubMed]
  6. Preveden, T.; Scarpellini, E.; Milić, N.; Luzza, F.; Abenavoli, L. Gut microbiota changes and chronic hepatitis C virus infection. Expert Rev. Gastroenterol. Hepatol. 2017, 11, 813–819. [Google Scholar] [CrossRef] [PubMed]
  7. Man, S.M. Inflammasomes in the gastrointestinal tract: Infection, cancer and gut microbiota homeostasis. Nat. Rev. Gastroenterol. Hepatol. 2018, 15, 721–737. [Google Scholar] [CrossRef] [PubMed]
  8. Debédat, J.; Clément, K.; Aron-Wisnewsky, J. Gut Microbiota dysbiosis in human obesity: Impact of bariatric surgery. Curr. Obes. Rep. 2019, 8, 229–242. [Google Scholar] [CrossRef] [PubMed]
  9. Toor, D.; Wsson, M.K.; Kumar, P.; Karthikeyan, G.; Kaushik, N.K.; Goel, C.; Singh, S.; Kumar, A.; Prakash, H. Dysbiosis disrupts gut immune homeostasis and promotes gastric diseases. Int. J. Mol. Sci. 2019, 20, E2432. [Google Scholar] [CrossRef] [PubMed]
  10. Uchiyama, K.; Naito, Y.; Takagi, T. Intestinal microbiome as a novel therapeutic target for local and systemic inflammation. Pharm. Ther. 2019, 199, 164–172. [Google Scholar] [CrossRef] [PubMed]
  11. Snell, L.M.; McGaha, T.L.; Brooks, D.G. Type I interferon in chronic virus infection and cancer. Trends Immunol. 2017, 38, 542–557. [Google Scholar] [CrossRef] [PubMed]
  12. Dagenais-Lussier, X.; Loucif, H.; Murira, A.; Laulhé, X.; Stäger, S.; Lamarre, A.; van Grevenynghe, J. Sustained IFN-I expression during established persistent viral infection: A “bad seed” for protective immunity. Viruses 2017, 10, E12. [Google Scholar] [CrossRef] [PubMed]
  13. Sohrab, S.S.; Kamal, M.A.; Atkinson, R.L.; Alawi, M.M.; Azhar, E.I. Viral infection and obesity: Current status and future prospective. Curr. Drug Metab. 2017, 18, 798–807. [Google Scholar] [CrossRef] [PubMed]
  14. Hainer, V.; Zamrazilová, H.; Kunešová, M.; Bendlová, B.; Aldhoon-Hainerová, I. Obesity and infection: Reciprocal causality. Physiol. Res. 2015, 64 (Suppl. 2), S105–S119. [Google Scholar]
  15. Voss, J.D.; Dhurandhar, N.V. Viral infections and obesity. Curr. Obes. Rep. 2017, 6, 28–37. [Google Scholar] [CrossRef] [PubMed]
  16. Pasarica, M.; Dhurandhar, N.V. Infectobesity: Obesity of infectious origin. Adv. Food Nutr. Res. 2007, 52, 61–102. [Google Scholar] [PubMed]
  17. Voss, J.D.; Leon, J.C.; Dhurandhar, N.V.; Robb, F.T. Pawnobiome: Manipulation of the hologenome within one host generation and beyond. Front. Microbiol. 2015, 6, 697. [Google Scholar] [CrossRef] [PubMed]
  18. Wu, D.; Sanin, D.E.; Everts, B.; Chen, Q.; Qiu, J.; Buck, M.D.; Patterson, A.; Smith, A.M.; Chang, C.H.; Liu, Z.; et al. Type 1 Interferons induce changes in core metabolism that are critical for immune function. Immunity 2016, 44, 1325–1336. [Google Scholar] [CrossRef] [PubMed]
  19. Nice, T.J.; Osborne, L.C.; Tomov, V.T.; Artis, D.; Wherry, E.J.; Virgin, H.W. Type I interferon receptor deficiency in dendritic cells facilitates systemic murine norovirus persistence despite enhanced adaptive immunity. PLoS Pathog. 2016, 12, e1005684. [Google Scholar] [CrossRef] [PubMed]
  20. Tan, V.P.K.; Ngim, C.F.; Lee, E.Z.; Ramadas, A.; Pong, L.Y.; Ng, J.I.; Hassan, S.S.; Ng, X.Y.; Dhanoa, A. The association between obesity and dengue virus (DENV) infection in hospitalised patients. PLoS ONE 2018, 13, e0200698. [Google Scholar] [CrossRef] [PubMed]
  21. Badawi, A.; Velummailum, R.; Ryoo, S.G.; Senthinathan, A.; Yaghoubi, S.; Vasileva, D.; Ostermeier, E.; Plishka, M.; Soosaipillai, M.; Arora, P. Prevalence of chronic comorbidities in dengue fever and West Nile virus: A systematic review and meta-analysis. PLoS ONE 2018, 13, e0200200. [Google Scholar] [CrossRef] [PubMed]
  22. Lake, J.E. The fat of the matter: Obesity and visceral adiposity in treated HIV infection. Curr. HIV/AIDS Rep. 2017, 14, 211–219. [Google Scholar] [CrossRef] [PubMed]
  23. Lake, J.E.; Stanley, T.L.; Apovian, C.M.; Bhasin, S.; Brown, T.T.; Capeau, J.; Currier, J.S.; Dube, M.P.; Falutz, J.; Grinspoon, S.K.; et al. Practical review of recognition and management of obesity and lipohypertrophy in human immunodeficiency virus infection. Clin. Infect. Dis. 2017, 64, 1422–1429. [Google Scholar] [CrossRef] [PubMed]
  24. Voss, J.D.; Atkinson, R.L.; Dhurandhar, N.V. Role of adenoviruses in obesity. Rev. Med. Virol. 2015, 25, 379–387. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Floyd, Z.E.; Stephens, J.M. Controlling a master switch of adipocyte development and insulin sensitivity: Covalent modifications of PPARγ. Biochim. Biophys. Acta 2012, 1822, 1090–1095. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Dubuisson, O.; Dhurandhar, E.J.; Krishnapuram, R.; Kirk-Ballard, H.; Gupta, A.K.; Hegde, V.; Floyd, E.; Gimble, J.M.; Dhurandhar, N.V. PPARgamma-independent increase in glucose uptake and adiponectin abundance in fat cells. Endocrinology 2011, 152, 3648–3660. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Dhurandhar, E.J.; Dubuisson, O.; Mashtalir, N.; Krishnapuram, R.; Hegde, V.; Dhurandhar, N.V. E4orf1: A novel ligand that improves glucose disposal in cell culture. PLoS ONE 2011, 6, e23394. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  28. Dhurandhar, N.V. Insulin sparing action of adenovirus 36 and its E4orf1 protein. J. Diabetes Complicat. 2013, 27, 191–199. [Google Scholar] [CrossRef] [PubMed]
  29. Vangipuram, S.D.; Yu, M.; Tian, J.; Stanhope, K.L.; Pasarica, M.; Havel, P.J.; Heydari, A.R.; Dhurandhar, N.V. Adipogenic human adenovirus-36 reduces leptin expression and secretion and increases glucose uptake by fat cells. Int. J. Obes. 2007, 31, 87–96. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  30. Sanchez, E.L.; Lagunoff, M. Viral activation of cellular metabolism. Virology 2015, 479–480, 609–618. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  31. Ridaura, V.K.; Faith, J.J.; Rey, F.E.; Cheng, J.; Duncan, A.E.; Kau, A.L.; Griffin, N.W.; Lombard, V.; Henrissat, B.; Bain, J.R.; et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 2013, 341, 1251214. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  32. Mills, S.; Shanahan, F.; Stanton, C.; Hill, C.; Coffey, A.; Ross, R.P. Movers and shakers: Influence of bacteriophages in shaping the mammalian gut microbiota. Gut Microbes. 2013, 4, 4–16. [Google Scholar] [CrossRef] [PubMed]
  33. Bahra, S.M.; Weidemann, B.J.; Castro, A.N.; Walsh, J.W.; deLeon, O.; Burnett, C.M.; Pearson, N.A.; Murry, D.J.; Grobe, J.L.; Kirby, J.R. Risperidone-induced weight gain is mediated through shifts in the gut microbiome and suppression of energy expenditure. EBioMedicine 2015, 2, 1725–1734. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Gogokhia, L.; Buhrke, K.; Bell, R.; Hoffman, B.; Brown, D.G.; Hanke-Gogokhia, C.; Ajami, N.J.; Wong, M.C.; Ghazaryan, A.; Valentine, J.F.; et al. Expansion of bacteriophages is linked to aggravated intestinal inflammation and colitis. Cell Host Microbe 2019, 25, 285–299. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Cheng, J.; Ke, Q.; Jin, Z.; Wang, H.; Kocher, O.; Morgan, J.P.; Zhang, J.; Crumpacker, C.S. Cytomegalovirus infection causes an increase of arterial blood pressure. PLoS Pathog. 2009, 5, e1000427. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  36. Hamer, M.; Batty, G.D.; Kivimäki, M. Obesity, metabolic health, and history of cytomegalovirus infection in the general population. J. Clin. Endocrinol. Metab. 2016, 101, 1680–1685. [Google Scholar] [CrossRef] [PubMed]
  37. Liberski, P.P.; Gajos, A.; Sikorska, B.; Lindenbaum, S. Kuru, the first human prion disease. Viruses 2019, 11, E232. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  38. Kim, Y.S.; Carp, R.I.; Callahan, S.M.; Wisniewski, H.M. Scrapie induced obesity in mice. J. Infect. Dis. 1987, 156, 402–405. [Google Scholar] [CrossRef] [PubMed]
  39. Carp, R.I.; Callahan, S.M.; Sersen, E.A.; Moretz, R.C. Preclinical changes in weight of scrapie-infected mice as a function of scrapie agent-mouse strain combination. Intervirology 1984, 21, 61–69. [Google Scholar] [CrossRef] [PubMed]
  40. Kim, Y.S.; Carp, R.I.; Callahan, S.M.; Wisniewski, H.M. Adrenal involvement in scrapie-induced obesity. Proc. Soc. Exp. Biol. Med. 1988, 189, 21–27. [Google Scholar] [CrossRef] [PubMed]
  41. Strom, A.; Yutzy, B.; Kruip, C.; Ooms, M.; Schloot, N.C.; Roden, M.; Scott, F.W.; Loewer, J.; Holznagel, E. Foodborne transmission of bovine spongiform encephalopathy to non-human primates results in preclinical rapid-onset obesity. PLoS ONE 2014, 9, e104343. [Google Scholar] [CrossRef] [PubMed]
  42. de Brito, G.; Lupinacci, F.C.; Beraldo, F.H.; Santos, T.G.; Roffé, M.; Lopes, M.H.; de Lima, V.C.; Martins, V.R.; Hajj, G.N. Loss of prion protein is associated with the development of insulin resistance and obesity. Biochem. J. 2017, 474, 2981–2991. [Google Scholar] [CrossRef] [PubMed]
  43. Kralj, D.; VirovićJukić, L.; Stojsavljević, S.; Duvnjak, M.; Smolić, M.; Čurčić, I.B. Hepatitis C virus, insulin resistance, and steatosis. J. Clin. Transl. Hepatol. 2016, 4, 66–75. [Google Scholar] [PubMed] [Green Version]
  44. Lazo, M.; Nwankwo, C.; Daya, N.R.; Thomas, D.L.; Mehta, S.H.; Juraschek, S.; Willis, K.; Selvin, E. Confluence of epidemics of hepatitis C, diabetes, obesity, and chronic kidney disease in the United States population. Clin. Gastroenterol. Hepatol. 2017, 15, 1957–1964. [Google Scholar] [CrossRef] [PubMed]
  45. Yen, Y.H.; Kee, K.M.; Chen, C.H.; Hu, T.H.; Lu, S.N.; Wang, J.H.; Hung, C.H. Sustained virological response and metabolic risk factors are associated with mortality in patients with chronic hepatitis C. PLoS ONE 2019, 14, e0208858. [Google Scholar] [CrossRef] [PubMed]
  46. Shields, L.E.; Jennings, J.; Liu, Q.; Lee, J.; Ma, W.; Blecha, F.; Miller, L.C.; Sang, Y. Cross-species genome-wide analysis reveals molecular and functional diversity of the unconventional interferon-ω subtype. Front. Immunol. 2019, 10, 1431. [Google Scholar] [CrossRef] [PubMed]
  47. Sang, Y.; Shields, L.E.; Sang, E.R.; Si, H.; Pigg, A.; Blecha, F. Ileal transcriptome analysis in obese rats induced by high-fat diets and an adenoviral infection. Int. J. Obes. 2019, 43, 2134–2142. [Google Scholar] [CrossRef] [PubMed]
  48. Terán-Cabanillas, E.; Hernández, J. Role of leptin and SOCS3 in inhibiting the type I interferon response during obesity. Inflammation 2017, 40, 58–67. [Google Scholar] [CrossRef] [PubMed]
  49. Nice, T.J.; Robinson, B.A.; Van Winkle, J.A. The role of interferon in persistent viral infection: Insights from murine norovirus. Trends Microbiol. 2018, 26, 510–524. [Google Scholar] [CrossRef] [PubMed]
  50. Suprunenko, T.; Hofer, M.J. Complexities of type I interferon biology: Lessons from LCMV. Viruses 2019, 11, E172. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  51. Ivashkiv, L.B.; Donlin, L.T. Regulation of type I interferon responses. Nat. Rev. Immunol. 2014, 14, 36–49. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  52. Xie, Y.; He, S.; Wang, J. MicroRNA-373 facilitates HSV-1 replication through suppression of type I IFN response by targeting IRF1. Biomed. Pharmacother. 2018, 97, 1409–1416. [Google Scholar] [CrossRef] [PubMed]
  53. Ru, J.; Sun, H.; Fan, H.; Wang, C.; Li, Y.; Liu, M.; Tang, H. MiR-23a facilitates the replication of HSV-1 through the suppression of interferon regulatory factor 1. PLoS ONE 2014, 9, e114021. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  54. Clement, M.; Marsden, M.; Stacey, M.A.; Abdul-Karim, J.; GimenoBrias, S.; Costa Bento, D.; Scurr, M.J.; Ghazal, P.; Weaver, C.T.; Carlesso, G.; et al. Cytomegalovirus-specific IL-10-producing CD4+ T cells are governed by type-I IFN-induced IL-27 and promote virus persistence. PLoS Pathog. 2016, 12, e1006050. [Google Scholar] [CrossRef] [PubMed]
  55. Marshall, E.E.; Geballe, A.P. Multifaceted evasion of the interferon response by cytomegalovirus. J. Interferon Cytokine Res. 2009, 29, 609–619. [Google Scholar] [CrossRef] [PubMed]
  56. Biolatti, M.; Dell’Oste, V.; Pautasso, S.; Gugliesi, F.; von Einem, J.; Krapp, C.; Jakobsen, M.R.; Borgogna, C.; Gariglio, M.; De Andrea, M.; et al. Human cytomegalovirus tegument protein pp65 (pUL83) dampens type I interferon production by inactivating the DNA sensor cGAS without affecting STING. J. Virol. 2018, 92, e01774-17. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  57. Ishibashi, D.; Homma, T.; Nakagaki, T.; Fuse, T.; Sano, K.; Satoh, K.; Mori, T.; Atarashi, R.; Nishida, N. Type I interferon protects neurons from prions in in vivo models. Brain 2019, 142, 1035–1050. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  58. Malachin, G.; Reiten, M.R.; Salvesen, Ø.; Aanes, H.; Kamstra, J.H.; Skovgaard, K.; Heegaard, P.M.H.; Ersdal, C.; Espenes, A.; Tranulis, M.A.; et al. Loss of prion protein induces a primed state of type I interferon-responsive genes. PLoS ONE 2017, 12, e0179881. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  59. Sandler, N.G.; Bosinger, S.E.; Estes, J.D.; Zhu, R.T.; Tharp, G.K.; Boritz, E.; Levin, D.; Wijeyesinghe, S.; Makamdop, K.N.; del Prete, G.Q.; et al. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature 2014, 511, 601–605. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  60. Scagnolari, C.; Monteleone, K.; Cacciotti, G.; Antonelli, G. Role of interferons in chronic hepatitis C infection. Curr. Drug Targets 2017, 18, 844–850. [Google Scholar] [CrossRef] [PubMed]
  61. Nan, Y.; Wu, C.; Zhang, Y.J. Interplay between Janus kinase/signal transducer and activator of transcription signaling activated by type I interferons and viral antagonism. Front. Immunol. 2017, 8, 1758. [Google Scholar] [CrossRef] [PubMed]
  62. García-Sastre, A. Ten strategies of interferon evasion by viruses. Cell Host Microbe 2017, 22, 176–184. [Google Scholar] [CrossRef] [PubMed]
  63. Huttunen, R.; Syrjänen, J. Obesity and the risk and outcome of infection. Int. J. Obes. 2013, 37, 333–340. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  64. Schroeder, B.O.; Backhed, F. Signals from the gut microbiota to distant organs in physiology and disease. Nat. Med. 2016, 22, 1079–1089. [Google Scholar] [CrossRef] [PubMed]
  65. Meijnikman, A.S.; Gerdes, V.E.; Nieuwdorp, M.; Herrema, H. Evaluating causality of gut microbiota in obesity and diabetes in humans. Endocr. Rev. 2017, 39, 133–153. [Google Scholar] [CrossRef] [PubMed]
  66. Sun, L.; Ma, L.; Ma, Y.; Zhang, F.; Zhao, C.; Nie, Y. Insights into the role of gut microbiota in obesity: Pathogenesis, mechanisms, and therapeutic perspectives. Protein Cell 2018, 9, 397–403. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  67. Dao, M.C.; Clément, K. Gut microbiota and obesity: Concepts relevant to clinical care. Eur. J. Intern. Med. 2018, 48, 18–24. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  68. Cadwell, K. The virome in host health and disease. Immunity 2015, 42, 805–813. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  69. Ogilvie, L.A.; Jones, B.V. The human gut virome: A multifaceted majority. Front. Microbiol. 2015, 6, 918. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  70. Yadav, H.; Jain, S.; Nagpal, R.; Marotta, F. Increased fecal viral content associated with obesity in mice. World J. Diabetes 2016, 7, 316–320. [Google Scholar] [CrossRef] [PubMed]
  71. Mukhopadhya, I.; Segal, J.P.; Carding, S.R.; Hart, A.L.; Hold, G.L. The gut virome: The ‘missing link’ between gut bacteria and host immunity? Ther. Adv. Gastroenterol. 2019, 12, 1756284819836620. [Google Scholar] [CrossRef] [PubMed]
  72. Lazear, H.M.; Schoggins, J.W.; Diamond, M.S. Shared and Distinct Functions of Type I and Type III Interferons. Immunity 2019, 50, 907–923. [Google Scholar] [CrossRef] [PubMed]
  73. Abt, M.C.; Osborne, L.C.; Monticelli, L.A.; Doering, T.A.; Alenghat, T.; Sonnenberg, G.F.; Paley, M.A.; Antenus, M.; Williams, K.L.; Erikson, J.; et al. Commensal bacteria calibrate the activation threshold of innate antiviral immunity. Immunity 2012, 37, 158–170. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  74. Ganal, S.C.; Sanos, S.L.; Kallfass, C.; Oberle, K.; Johner, C.; Kirschning, C.; Lienenklaus, S.; Weiss, S.; Staeheli, P.; Aichele, P.; et al. Priming of natural killer cells by nonmucosal mononuclear phagocytes requires instructive signals from commensal microbiota. Immunity 2012, 37, 171–186. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  75. Kawashima, T.; Kosaka, A.; Yan, H.; Guo, Z.; Uchiyama, R.; Fukui, R.; Kaneko, D.; Kumagai, Y.; You, D.J.; Carreras, J.; et al. Double-stranded RNA of intestinal commensal but not pathogenic bacteria triggers production of protective interferon-β. Immunity 2013, 38, 1187–1197. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  76. Liu, Q.; Miller, L.C.; Blecha, F.; Sang, Y. Reduction of infection by inhibiting mTOR pathway is associated with reversed repression of type I interferon by porcine reproductive and respiratory syndrome virus. J. Gen. Virol. 2017, 98, 1316–1328. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  77. González-Navajas, J.M.; Lee, J.; David, M.; Raz, E. Immunomodulatory functions of type I interferons. Nat. Rev. Immunol. 2012, 12, 125–135. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  78. Wang, H.; Brown, J.; Garcia, C.A.; Tang, Y.; Benakanakere, M.R.; Greenway, T.; Alard, P.; Kinane, D.F.; Martin, M. The role of glycogen synthase kinase 3 in regulating IFN-β-mediated IL-10 production. J. Immunol. 2011, 186, 675–684. [Google Scholar] [CrossRef] [PubMed]
  79. Alsaggar, M.; Mills, M.; Liu, D. Interferon beta overexpression attenuates adipose tissue inflammation and high-fat diet-induced obesity and maintains glucose homeostasis. Gene Ther. 2017, 24, 60–66. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  80. Fritsch, S.D.; Weichhart, T. Effects of interferons and viruses on metabolism. Front. Immunol. 2016, 7, 630. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  81. Raniga, K.; Liang, C. Interferons: Reprogramming the metabolic network against viral infection. Viruses 2018, 10, E36. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  82. York, A.G.; Williams, K.J.; Argus, J.P.; Zhou, Q.D.; Brar, G.; Vergnes, L.; Gray, E.E.; Zhen, A.; Wu, N.C.; Yamada, D.H.; et al. Limiting cholesterol biosynthetic flux spontaneously engages type I IFN signaling. Cell 2015, 163, 1716–1729. [Google Scholar] [CrossRef] [PubMed]
  83. Mazzon, M.; Mercer, J. Lipid interactions during virus entry and infection. Cell Microbiol. 2014, 16, 1493–1502. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  84. Chukkapalli, V.; Heaton, N.S.; Randall, G. Lipids at the interface of virus-host interactions. Curr. Opin. Microbiol. 2012, 15, 512–518. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  85. Osuna-Ramos, J.F.; Reyes-Ruiz, J.M.; Del Ángel, R.M. The Role of Host Cholesterol During Flavivirus Infection. Front. Cell. Infect. Microbiol. 2018, 8, 388. [Google Scholar] [CrossRef] [PubMed]
  86. Liu, S.Y.; Aliyari, R.; Chikere, K.; Li, G.; Marsden, M.D.; Smith, J.K.; Pernet, O.; Guo, H.; Nusbaum, R.; Zack, J.A.; et al. Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol. Immunity 2013, 38, 92–105. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  87. Soudani, N.; Hage-Sleiman, R.; Karam, W.; Dbaibo, G.; Zaraket, H. Ceramide Suppresses Influenza A Virus Replication In Vitro. J. Virol. 2019, 93, e00053-19. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  88. Burke, J.D.; Platanias, L.C.; Fish, E.N. Beta interferon regulation of glucose metabolism is PI3K/Akt dependent and important for antiviral activity against coxsackievirus B3. J. Virol. 2014, 88, 3485–3495. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  89. Pantel, A.; Teixeira, A.; Haddad, E.; Wood, E.G.; Steinman, R.M.; Longhi, M.P. Direct type I IFN but not MDA5/TLR3 activation of dendritic cells is required for maturation and metabolic shift to glycolysis after poly IC stimulation. PLoS Biol. 2014, 12, e1001759. [Google Scholar] [CrossRef] [PubMed]
  90. Grunert, T.; Leitner, N.R.; Marchetti-Deschmann, M.; Miller, I.; Wallner, B.; Radwan, M.; Vogl, C.; Kolbe, T.; Kratky, D.; Gemeiner, M.; et al. A comparative proteome analysis links tyrosine kinase 2 (Tyk2) to the regulation of cellular glucose and lipid metabolism in response to poly(I:C). J. Proteom. 2011, 74, 2866–2880. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  91. Hedl, M.; Yan, J.; Abraham, C. IRF5 and IRF5 disease-risk variants increase glycolysis and human M1 macrophage polarization by regulating proximal signaling and Akt2 activation. Cell Rep. 2016, 16, 2442–2455. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  92. Lewis, J.A.; Huq, A.; Najarro, P. Inhibition of mitochondrial function by interferon. J. Biol. Chem. 1996, 271, 13184–13190. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  93. Kaur, S.; Sassano, A.; Majchrzak-Kita, B.; Baker, D.P.; Su, B.; Fish, E.N.; Platanias, L.C. Regulatory effects of mTORC2 complexes in type I IFN signaling and in the generation of IFN responses. Proc. Natl. Acad. Sci. USA 2012, 109, 7723–7728. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  94. Su, X.; Yu, Y.; Zhong, Y.; Giannopoulou, E.G.; Hu, X.; Liu, H.; Cross, J.R.; Rätsch, G.; Rice, C.M.; Ivashkiv, L.B. Interferon-gamma regulates cellular metabolism and mRNA translation to potentiate macrophage activation. Nat. Immunol. 2015, 16, 838–849. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  95. Vlahos, R.; Stambas, J.; Selemidis, S. Suppressing production of reactive oxygen species (ROS) for influenza A virus therapy. Trends Pharm. Sci. 2012, 33, 3–8. [Google Scholar] [CrossRef] [PubMed]
  96. Wu, T.; Ma, F.; Ma, X.; Jia, W.; Pan, E.; Cheng, G.; Chen, L.; Sun, C. Regulating innate and adaptive immunity for controlling SIV infection by 25-hydroxycholesterol. Front. Immunol. 2018, 9, 2686. [Google Scholar] [CrossRef] [PubMed]
  97. Yim, H.Y.; Yang, Y.; Lim, J.S.; Lee, M.S.; Zhang, D.E.; Kim, K.I. The mitochondrial pathway and reactive oxygen species are critical contributors to interferon-α/β-mediated apoptosis in Ubp43-deficient hematopoietic cells. Biochem. Biophys. Res. Commun. 2012, 423, 436–440. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  98. Watanabe, Y.; Suzuki, O.; Haruyama, T.; Akaike, T. Interferon-gamma induces reactive oxygen species and endoplasmic reticulum stress at the hepatic apoptosis. J. Cell. Biochem. 2003, 89, 244–253. [Google Scholar] [CrossRef] [PubMed]
  99. Bougnoux, P.; Salem, N.; Lyons, C.; Hoffman, T. Alteration in the membrane fatty acid composition of human lymphocytes and cultured transformed cells induced by interferon. Mol. Immunol. 1985, 22, 1107–1113. [Google Scholar] [CrossRef]
  100. Pfeffer, L.M.; Landsberger, F.R.; Tamm, I. Beta-interferon-induced time-dependent changes in the plasma membrane lipid bilayer of cultured cells. J. Interferon Res. 1981, 1, 613–620. [Google Scholar] [CrossRef] [PubMed]
  101. Furlong, S.T.; Mednis, A.; Remold, H.G. Interferon-gamma stimulates lipid metabolism in human monocytes. Cell. Immunol. 1992, 143, 108–117. [Google Scholar] [CrossRef]
  102. Chatterjee, S.; Cheung, H.C.; Hunter, E. Interferon inhibits Sendai virus-induced cell fusion: An effect on cell membrane fluidity. Proc. Natl. Acad. Sci. USA 1982, 79, 835–839. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  103. Kroczynska, B.; Rafidi, R.L.; Majchrzak-Kita, B.; Kosciuczuk, E.M.; Blyth, G.T.; Jemielity, J.; Warminska, Z.; Saleiro, D.; Mehrotra, S.; Arslan, A.D.; et al. Interferon gamma (IFNgamma) signaling via mechanistic target of rapamycin complex 2 (mTORC2) and regulatory effects in the generation of type II interferon biological responses. J. Biol. Chem. 2016, 291, 2389–2396. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  104. Chaurasia, B.; Tippetts, T.S.; Monibas, R.M.; Liu, J.; Li, Y.; Wang, L.; Wilkerson, J.L.; Sweeney, C.R.; Pereira, R.F.; Sumida, D.H.; et al. Targeting a ceramide double bond improves insulin resistance and hepatic steatosis. Science 2019, 365, 386–392. [Google Scholar] [CrossRef] [PubMed]
  105. Ottenlinger, F.M.; Mayer, C.A.; Ferreirós, N.; Schreiber, Y.; Schwiebs, A.; Schmidt, K.G.; Ackermann, H.; Pfeilschifter, J.M.; Radeke, H.H. Interferon-beta increases plasma ceramides of specific chain length in multiple sclerosis patients, unlike fingolimod or natalizumab. Front. Pharmacol. 2016, 7, 412. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  106. O’Shea, D.; Hogan, A.E. Dysregulation of natural killer cells in obesity. Cancers 2019, 11, E573. [Google Scholar]
  107. Ghazarian, M.; Revelo, X.S.; Nøhr, M.K.; Luck, H.; Zeng, K.; Lei, H.; Tsai, S.; Schroer, S.A.; Park, Y.J.; Chng, M.H.Y.; et al. Type I interferon responses drive intrahepatic T cells to promote metabolic syndrome. Sci. Immunol. 2017, 2, eaai7616. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  108. Easterbrook, J.D.; Dunfee, R.L.; Schwartzman, L.M.; Jagger, B.W.; Sandouk, A.; Kash, J.C.; Memoli, M.J.; Taubenberger, J.K. Obese mice have increased morbidity and mortality compared to non-obese mice during infection with the 2009 pandemic H1N1 influenza virus. Influenza Other Respir. Viruses 2011, 5, 418–425. [Google Scholar] [CrossRef] [PubMed]
  109. Weber, K.J.; Sauer, M.; He, L.; Tycksen, E.; Kalugotla, G.; Razani, B.; Schilling, J.D. PPARγ deficiency suppresses the release of IL-1β and IL-1α in macrophages via a type 1 IFN-dependent mechanism. J. Immunol. 2018, 201, 2054–2069. [Google Scholar] [CrossRef] [PubMed]
  110. McGillicuddy, F.C.; Chiquoine, E.H.; Hinkle, C.C.; Kim, R.J.; Shah, R.; Roche, H.M.; Smyth, E.M.; Reilly, M.P. Interferon gamma attenuates insulin signaling, lipid storage, and differentiation in human adipocytes via activation of the JAK/STAT pathway. J. Biol. Chem. 2009, 284, 31936–31944. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  111. Wieser, V.; Adolph, T.E.; Grander, C.; Grabherr, F.; Enrich, B.; Moser, P.; Moschen, A.R.; Kaser, S.; Tilg, H. Adipose type I interferon signalling protects against metabolic dysfunction. Gut 2018, 67, 157–165. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  112. Ying, W.; Kanameni, S.; Chang, C.A.; Nair, V.; Safe, S.; Bazer, F.W.; Zhou, B. Interferon tau alleviates obesity-induced adipose tissue inflammation and insulin resistance by regulating macrophage polarization. PLoS ONE 2014, 9, e98835. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  113. Interferons for Hepatitis C: Understanding the Long-Term Side Effects. Available online: https://www.healthline.com/health/hepatitis-c/interferons-long-term-effects (accessed on 10 October 2019).
Biomolecules 09 00726 g001 550
Figure 1. Intrinsic interferon (IFN) response to microbiota tonic induction may suppress obesity in addition to its role in potentiating rapid antiviral response. In homeostatic situation, gut epithelia and the underlying leukocytes (mainly macrophages and dendritic cells, for example) sense natural shedding of microbial molecules from microbiota (particularly virobiota) and sustain an intrinsic expression of innate immune IFNs, particularly including IFN-β and probably IFN-λ. Acting through a non-canonical AKT-mTOR pathway, intrinsic IFNs signal IL-10/TGF production and contribute to maintain an anti-inflammatory microenvironment, which attenuates meta-inflammation and adipogenesis related to visceral obesity. The anti-obesity effect of transfecting IFN-β was recently demonstrated in addition to its role in potentiating rapid antiviral response via IFN autocrine loop of regulation. Abbreviations: AKT-mTOR, protein kinase B and mammalian target of rapamycin pathway; CREB, cAMP response element binding protein; IFN, interferon; IFNAR, type I IFN receptor; IFNLR, type III IFN receptor; IRF, IFN regulatory factor; IL-10, interleukin 10; PAMP, pathogenic associated molecular pattern; TGF, transforming growth factor; and TLR, Toll-like receptor.
Figure 1. Intrinsic interferon (IFN) response to microbiota tonic induction may suppress obesity in addition to its role in potentiating rapid antiviral response. In homeostatic situation, gut epithelia and the underlying leukocytes (mainly macrophages and dendritic cells, for example) sense natural shedding of microbial molecules from microbiota (particularly virobiota) and sustain an intrinsic expression of innate immune IFNs, particularly including IFN-β and probably IFN-λ. Acting through a non-canonical AKT-mTOR pathway, intrinsic IFNs signal IL-10/TGF production and contribute to maintain an anti-inflammatory microenvironment, which attenuates meta-inflammation and adipogenesis related to visceral obesity. The anti-obesity effect of transfecting IFN-β was recently demonstrated in addition to its role in potentiating rapid antiviral response via IFN autocrine loop of regulation. Abbreviations: AKT-mTOR, protein kinase B and mammalian target of rapamycin pathway; CREB, cAMP response element binding protein; IFN, interferon; IFNAR, type I IFN receptor; IFNLR, type III IFN receptor; IRF, IFN regulatory factor; IL-10, interleukin 10; PAMP, pathogenic associated molecular pattern; TGF, transforming growth factor; and TLR, Toll-like receptor.
Biomolecules 09 00726 g001
Biomolecules 09 00726 g002 550
Figure 2. Antiviral IFN stimulation and the effect on energy and lipid metabolism. Counteracting viral infections, which seize the cell energy and lipid metabolism for viral production but enhance fatty acid (FA) and cholesterol synthesis, effective IFN response leads to an antiviral state through an IFN autocrine or paracrine regulatory loop. The induction of antiviral state is accompanied by a general arrest of protein and lipid metabolism. The IFN suppression of lipid metabolism is multifaceted such as directly repressing the synthesis of FA and cholesterol, and regulating via the upstream regulators of AMPK and mTOR complex. In addition, IFNs have been also implicated in the regulation of glycolysis, TCA cycle, and cholesterol transport to facilitate cell antiviral response. Taking together, the effective IFN response, especially that during acute phases of antiviral responses, is unlikely to induce obesity and meta-inflammation underlying obesity; however, the prolonged IFN responses during chronic viral infections might be an adipogenic drive in an opposite way (Figure 3). Abbreviations: acetyl-CoA, acetyl coenzyme A; Akt/PI3K/mTOR, phosphatidylinositol-3-kinase (PI3K)/Akt and the mammalian target of rapamycin (mTOR) signaling pathway; AMPK, 5-adenosine monophosphate-activated protein kinase; FA, fatty acid; FAO, fatty acid oxidation; IFN-I, type I interferon; 25HC, 25-hydroxycholesterol; ROS, reactive oxygen species; SREBP, sterol regulatory binding protein; TCA cycle, tricarboxylic acid cycle. Adapted from [80,81] with a permission.
Figure 2. Antiviral IFN stimulation and the effect on energy and lipid metabolism. Counteracting viral infections, which seize the cell energy and lipid metabolism for viral production but enhance fatty acid (FA) and cholesterol synthesis, effective IFN response leads to an antiviral state through an IFN autocrine or paracrine regulatory loop. The induction of antiviral state is accompanied by a general arrest of protein and lipid metabolism. The IFN suppression of lipid metabolism is multifaceted such as directly repressing the synthesis of FA and cholesterol, and regulating via the upstream regulators of AMPK and mTOR complex. In addition, IFNs have been also implicated in the regulation of glycolysis, TCA cycle, and cholesterol transport to facilitate cell antiviral response. Taking together, the effective IFN response, especially that during acute phases of antiviral responses, is unlikely to induce obesity and meta-inflammation underlying obesity; however, the prolonged IFN responses during chronic viral infections might be an adipogenic drive in an opposite way (Figure 3). Abbreviations: acetyl-CoA, acetyl coenzyme A; Akt/PI3K/mTOR, phosphatidylinositol-3-kinase (PI3K)/Akt and the mammalian target of rapamycin (mTOR) signaling pathway; AMPK, 5-adenosine monophosphate-activated protein kinase; FA, fatty acid; FAO, fatty acid oxidation; IFN-I, type I interferon; 25HC, 25-hydroxycholesterol; ROS, reactive oxygen species; SREBP, sterol regulatory binding protein; TCA cycle, tricarboxylic acid cycle. Adapted from [80,81] with a permission.
Biomolecules 09 00726 g002
Biomolecules 09 00726 g003 550
Figure 3. A reciprocal causality of obesity and chronic viral infections. High-fat diet and viral infection (particularly chronic viral infections) may independently (or synergistically in most time) induce dysbiosis of gut microbiota leading to gut inflammation and leaking, which at least partly results from prolonged IFN production upon chronic viral infection and underlies systemic inflammation of obesity. In turn, through the production of long-chain fatty acid (LFA) and leptin by expanding adipocytes, obesity is accompanied with meta-inflammation (enhanced by LFA) and susceptibility to viral infections (through suppression of IFN antiviral signaling by leptin induction of SOCS3 signaling). Abbreviations: NF-κB, nuclear factor-kappa B; P-STAT, phosphorylated signal transducer and activator of transcription; RIG-I, retinoic acid-inducible gene I; SOCS3, suppressor of cytokine signaling 3; TNF, tumor necrosis factor; and that in the legend of Figure 1.
Figure 3. A reciprocal causality of obesity and chronic viral infections. High-fat diet and viral infection (particularly chronic viral infections) may independently (or synergistically in most time) induce dysbiosis of gut microbiota leading to gut inflammation and leaking, which at least partly results from prolonged IFN production upon chronic viral infection and underlies systemic inflammation of obesity. In turn, through the production of long-chain fatty acid (LFA) and leptin by expanding adipocytes, obesity is accompanied with meta-inflammation (enhanced by LFA) and susceptibility to viral infections (through suppression of IFN antiviral signaling by leptin induction of SOCS3 signaling). Abbreviations: NF-κB, nuclear factor-kappa B; P-STAT, phosphorylated signal transducer and activator of transcription; RIG-I, retinoic acid-inducible gene I; SOCS3, suppressor of cytokine signaling 3; TNF, tumor necrosis factor; and that in the legend of Figure 1.
Biomolecules 09 00726 g003
Table
Table 1. Adipogenic viruses or virus-like agents and virus-interferon (IFN) interaction *.
Table 1. Adipogenic viruses or virus-like agents and virus-interferon (IFN) interaction *.
Adipogenic Viruses * Biomolecules 09 00726 i001
Adenoviridae [15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30]		 Biomolecules 09 00726 i002
Gut Phages [31,32,33,34]		 Biomolecules 09 00726 i003
Herpesviridae [35,36]		 Biomolecules 09 00726 i004
Slow Virus (Prion) [37,38,39,40,41,42]		 Biomolecules 09 00726 i005
Other Viruses [21,22,23,43,44,45]
Natural hosts or
Livestock reservoirs		Avian: SMAM1
Human:
Ad-5/9/31/36/37		Gut phages likely in all animalsHuman:
HSV-1, CMV, HHV8		Sheep: Scrapie
Cattle: BSE/CJD
Human: Kuru		Avian: RAV7
Sheep/Horse: BDV
Human: DENV, HIV, HCV
Lipogenic in vitroAd-5/9/31/36/37
Cause adipocyte differen-tiation and lipogenesis		Unknown Increase lipogenesis in cellsUnknownHCV enhances lipid
synthesis, and CDV
enlarges adipocytes
Adipogenic in animalsAd-36, Ad-37: chickens
Ad-36, Ad-5: mice
Ad-36: rats, marmosets		Gut phages following
risperidone treatment: mice 		UnknownBSE: primates
Scrapie, CJD
variants: mice		BDV, CDV: mice
RAV7: chickens
Obesity-association in humansAd-5: childhood obesity, Ad-36: childhood, adult obesity and BMI
SMAM-1: BMI		Adipogenic gut
microbe transfer
associated with heavier
human donor 		CMV: metabolic
Syndrome
HSV-1: adult obesity		Kuru obesity and/or
bulimia during
early disease in
humans		HCV genotype 3:
insulin resistance in humans
DENV: children obesity
HIV: obesity in patients on ART
Obesity during persistent viral infections? [13,14,15]YESUnknown, but the effect of gut phages on microbiota is persistent YESYESYES, especially in human cases
Suppression of acute IFN antiviral response, and [43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63]Yes, through E1A geneUnknownYes, HSV-1 through miRNA; and CMV has multiple IFN-antagonistic mechanisms Infecting prions suppress interferon expressionMultiple IFN-antagonistic mechanism in DENV, HIV, and HCV
Cause prolonged IFN production upon chronic infection [43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63]Likely yes in adipogenic Ad-36 infection, and persistent enteric infection in childrenExpansion of gut phages induces intestinal inflammation via TLR9-mediated IFN reactionCMV exploits prolonged IFN production to induce IL-27 production and chronic infection Typically chronic, as reflected by the term of “slow virus”Prolonged IFNs promote HCV and retroviral chronicity.
*Abbreviations: Ad, adenovirus; ART, HIV Antiretroviral therapy; BDV, borna disease virus; BMI, body mass index; CMV, cytomegalovirus; DENV, dengue fever virus; HHV, human herpesvirus; HCV, hepatitis C virus; HSV-1, herpes simplex virus 1; IL, interleukin; RAV, Rous-associated virus; SMAM, an avian adenovirus from India; TLR9, Toll-like receptor 9. Contents in Row 1–4 adapted from Voss and Dhurandhar (2017) [15].

Share and Cite

MDPI and ACS Style

Tian, Y.; Jennings, J.; Gong, Y.; Sang, Y. Viral Infections and Interferons in the Development of Obesity. Biomolecules 2019, 9, 726. https://doi.org/10.3390/biom9110726

AMA Style

Tian Y, Jennings J, Gong Y, Sang Y. Viral Infections and Interferons in the Development of Obesity. Biomolecules. 2019; 9(11):726. https://doi.org/10.3390/biom9110726

Chicago/Turabian Style

Tian, Yun, Jordan Jennings, Yuanying Gong, and Yongming Sang. 2019. "Viral Infections and Interferons in the Development of Obesity" Biomolecules 9, no. 11: 726. https://doi.org/10.3390/biom9110726

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop